GlaxoSmithKline has received a bid approach for its thrombosis drug brands Arixtra and Fraxiparine, which last year bought in sales of more than £400m.
South Africa's Aspen Pharmacare's offer is for the brands, plus the French factory that makes them. Some 1,000 Glaxo employees will transfer to Aspen if the deal goes through.
Britain's biggest pharmaceutical group said the proposed deal was "aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline."Reuse content